Drug Trial Radar · NCT03906006
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 17, 2018
Primary completion
Jun 20, 2019
Study completion Jun 20, 2019
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
Conditions
- Gout
- Hyperuricemia
Interventions
ABP-671Drug
Drug: ABP-671, single oral dose
PlaceboOther
Other: Placebo, single oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: baseline to 7 days
- Maximum tolerable doseTime frame: baseline to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.